Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel
and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and
will allow estimation of prostate-specific antigen (PSA) response in men with metastatic
castration-resistant prostate cancer (mCRPC).